Drugs / Human Intravenous Immunoglobulins
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04701034 Comparator | Jan 2021 → Apr 2024 | habitual spontaneous abortion, pregnancy disorder with abortive outcome, pregnancy loss, recurrent, 4 | Aalborg University Hospital | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Human Intravenous Immunoglobulins | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04701034 ↗ |
| Known as | Privigen | “Human Intravenous Immunoglobulins, (Privigen (R), CLS Behring)” NCT04701034 ↗ |
| Modality | Protein / enzyme biologic | “IVIg (Privigen) consist of a broad spectrum of structurally and functionally intact IgG antibodies.” NCT04701034 ↗ |
| Route | Intravenous | “First infusion (IVIg or Albumin) is given within 5 workings days before and 2 working days after embryo transfer.” NCT04701034 ↗ |